6 completed, 2 recruiting, 2 terminated, 1 active not recruiting. 12 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 6, Recruiting 2, Terminated 2, Active not recruiting 1, Withdrawn 1 |
Follow Bioprojet: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Proof of Concept Study on BP1.4979 Effect on Essential Tremor BP1.4979, Placebo - Essential Tremor | Phase 2 | Recruiting | Bioprojet | 50 | 2025-09-17 | 2025-12-16 |
| Proof of Concept Study on BP1.4979 Effect on Primary Premature Ejaculation BP1.4979, Placebo - Premature (Early) Ejaculation | Phase 2 | Recruiting | Bioprojet | 60 | 2025-09-15 | 2025-10-06 |
| Proof of Concept Study on Pitolisant Effect on Autism Spectrum Disorders in Children and Adolescents Pitolisant, Placebo - Autism Spectrum Disorder | Phase 2 | Active not recruiting | Bioprojet | 62 | 2023-12-20 | 2025-10-02 |
| Proof of Concept Study Evaluating BP1.3656 in Patients With Fatigue Following Ischemic Stroke BP1.3656 - Fatigue | Phase 2 | Terminated | Bioprojet | 5 | 2023-01-20 | 2024-08-09 |
| Pilot Study on BP1.4979 Effect on Binge Eating Disorders BP1.4979 active drug, Placebo - Binge-Eating Disorder | Phase 2 | Completed | Bioprojet | 67 | 2022-03-07 | 2025-11-25 |
| Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome BP 1.4979, Placebo - Restless Legs Syndrome | Phase 2 | Terminated | Bioprojet | 29 | 2018-02-06 | 2020-07-30 |
| Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment BP1.3656 low dose, BP1.3656 intermediate dose, Placebo - Alcohol Use Disorder | Phase 2 | Completed | Bioprojet | 210 | 2018-01-09 | 2022-01-21 |
| A Trial Evaluating Pitolisant (BF2.649) in Alcohol Use Disorder Treatment Pitolisant (BF2.649), Placebo - Alcohol Abuse, Nervous System | Phase 2 | Withdrawn | Bioprojet | 2016-10-01 | 2017-01-12 | |
| Efficacy and Safety of BP1.4979 in Smoking Cessation BP1.4979, Placebo - Tobacco Addiction | Phase 2 | Completed | Bioprojet | 219 | 2013-02-01 | 2015-01-21 |
| Dose-range Finding Study of BF2.649 Effect on Patients With Obstructive Sleep Apnea (OSA) BF2.649, Placebo - Obstructive Sleep Apnoea, Excessive Daytime Sleepiness | Phase 2 | Completed | Bioprojet | 110 | 2010-10-01 | 2012-06-15 |
| Study to Demonstrate Cognitive Enhancing Effects of BF2.649 BF2.649, Placebo - Schizophrenia | Phase 2 | Completed | University of Texas Southwestern Medical Center | 52 | 2008-06-01 | 2019-04-23 |
| Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients Placebo, BF 2.649 5 mg, BF 2.649 10 mg - Excessive Daytime Sleepiness, Parkinson's Disease | Phase 2 | Completed | Bioprojet | 108 | 2007-10-01 | 2012-06-11 |
Disorders of Excessive Somnolence (2) · Alcohol-Induced Disorders, Nervous System (1) · Alcoholism (1) · Autism Spectrum Disorder (1) · Binge-Eating Disorder (1) · Essential Tremor (1) · Fatigue (1) · Parkinson Disease (1) · Premature Birth (1) · Restless Legs Syndrome (1) · Schizophrenia (1) · Sleep Apnea, Obstructive (1) · Sleep Wake Disorders (1)
pitolisant (5) · Starch (1)
France (10) · Bulgaria (1) · Italy (1) · Russia (1) · Spain (1) · Switzerland (1) · United Kingdom (1) · United States (1)
Carol A Tamminga, MD (1) · Carsten Moeller (1) · Claudio Bassetti, MD, Prof. (1) · Evelyne De Paillette, MD (1) · Evgeny Krupitsky, Pr (1) · Imad Ghorayeb, MD (1) · Olivier Bonnot, MD, Prof. (1)
2017 (1)